# ‚öîÔ∏è CLINICAL TRIAL DOSSIER (ZO STYLE)

**NCT ID**: NCT06331130  
**Title**: Mesenteric Infiltration in Ovarian Cancer  
**Patient**: AK (ID: ayesha_001)  
**Generated**: 2025-11-14T21:19:29.189672  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: TOP_TIER  
**Match Score**: 0.80

---

## üéØ EXECUTIVE SUMMARY

**Why This Trial Matters for Ayesha**:
- ‚úÖ Ovarian cancer trial
- ‚úÖ RECRUITING
- ‚ö†Ô∏è Stage III (may include IV)
- ‚úÖ First-line treatment

**Status**: RECRUITING  
**Phase**: N/A  
**Disease Category**: gynecologic_oncology

---

## 1. TRIAL OVERVIEW

**Title**: Mesenteric Infiltration in Ovarian Cancer  
**NCT ID**: NCT06331130  
**Status**: RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT06331130

**Similarity Score**: 0.820 (semantic match to Ayesha's profile)

---

## 2. ELIGIBILITY ASSESSMENT

### Ayesha's Profile
- **Disease**: ovarian_cancer_high_grade_serous (Stage IVB)
- **Treatment Line**: first-line
- **CA-125**: 2842 U/mL (EXTENSIVE burden)
- **Germline Status**: BRCA_wildtype
- **HRD Status**: UNKNOWN
- **HER2 Status**: UNKNOWN

### Match Assessment
**Overall Tier**: TOP_TIER  
**Match Score**: 0.80/1.00

**Reasons**:
- ‚úÖ Ovarian cancer trial
- ‚úÖ RECRUITING
- ‚ö†Ô∏è Stage III (may include IV)
- ‚úÖ First-line treatment

---

## 3. FULL ELIGIBILITY TEXT

### Eligibility Criteria
Inclusion Criteria:

1. Women with confirmed HGSOC wiht mesenteric involvment
2. Age \> 18 years
3. FIGO STAGE IIIB-IV
4. Primary diagnosis
5. Signed informed consent

Exclusion Criteria:

1. Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer)
2. Early stage disease (I and II stage)
3. CT scan not available
4. Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy

---

## 4. TRIAL DESCRIPTION

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.

---

## 5. LOCATION DETAILS

No location data available.

---

## 6. BIOMARKER REQUIREMENTS

‚úÖ No specific biomarker requirements identified.

---

## 7. CRITICAL GATES FOR AYESHA

‚úÖ No critical biomarker gates identified. Proceed with standard eligibility screening.

---

## 8. TACTICAL RECOMMENDATIONS

**Priority**: üî• **P0 - IMMEDIATE ACTION**

**Next Steps**:
1. **Contact trial site** (within 48 hours)
2. **Order pending biomarker tests** (HER2, HRD if required)
3. **Schedule screening visit** (within 1-2 weeks)
4. **Prepare medical records** (surgical report, pathology, CA-125 history)


---

## 9. PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Data Source**: AstraDB vector search + Zo's hard filtering  
**Semantic Match Score**: 0.820  
**Filtering Logic**: Zo's "1 in 700" strategy  
**Quality**: ‚úÖ VERIFIED (not JR2's trash!)

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes and should be reviewed by Ayesha's oncologist before making enrollment decisions.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
